Total Payments
$213.14
2023 Payments
$26.06
Companies
4
Transactions
13
Medicare Patients
1,808
Medicare Billing
$330,936
Payment Breakdown by Category
Food & Beverage$200.87 (94.2%)
Education$12.27 (5.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $200.87 | 12 | 94.2% |
| Education | $12.27 | 1 | 5.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| The Medicines Company | $107.68 | 7 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $41.79 | 3 | $0 (2017) |
| Shionogi Inc | $38.33 | 2 | $0 (2023) |
| Melinta Therapeutics, Inc. | $25.34 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $26.06 | 1 | Shionogi Inc ($26.06) |
| 2020 | $12.27 | 1 | Shionogi Inc ($12.27) |
| 2019 | $25.34 | 1 | Melinta Therapeutics, Inc. ($25.34) |
| 2018 | $12.00 | 1 | The Medicines Company ($12.00) |
| 2017 | $137.47 | 9 | The Medicines Company ($95.68) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/25/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: Infections and Infectious Diseases | ||||||
| 07/28/2020 | Shionogi Inc | Fetroja (Drug) | Education | In-kind items and services | $12.27 | General |
| Category: Infections and Infectious Diseases | ||||||
| 01/11/2019 | Melinta Therapeutics, Inc. | Vabomere (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: ANTIBIOTICS | ||||||
| 01/04/2018 | The Medicines Company | VABOMERE (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/24/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/27/2017 | The Medicines Company | MINOCIN IV (Drug) | Food and Beverage | In-kind items and services | $12.40 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/10/2017 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/04/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/27/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/20/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/20/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/13/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/30/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 183 | 331 | $73,363 | $25,447 |
| 2022 | 5 | 405 | 1,069 | $251,950 | $76,050 |
| 2021 | 5 | 592 | 1,620 | $360,285 | $117,205 |
| 2020 | 5 | 628 | 1,527 | $314,612 | $112,233 |
Total Patients
1,808
Total Services
4,547
Medicare Billing
$330,936
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 92 | 221 | $45,052 | $14,286 | 31.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 45 | 48 | $11,140 | $5,092 | 45.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 34 | $10,438 | $3,312 | 31.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 16 | $5,200 | $2,270 | 43.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 12 | $1,533 | $487.78 | 31.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 193 | 659 | $131,800 | $38,305 | 29.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 85 | 276 | $69,000 | $23,199 | 33.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 44 | 45 | $24,750 | $7,197 | 29.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 56 | 58 | $21,750 | $6,361 | 29.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 27 | 31 | $4,650 | $989.08 | 21.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 293 | 1,057 | $202,880 | $62,950 | 31.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 88 | 334 | $84,725 | $28,560 | 33.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 118 | 127 | $40,085 | $14,361 | 35.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 56 | 60 | $26,925 | $9,992 | 37.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 37 | 42 | $5,670 | $1,341 | 23.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 319 | 988 | $177,840 | $58,592 | 32.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 107 | 331 | $85,067 | $28,298 | 33.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 76 | 77 | $25,025 | $12,835 | 51.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 106 | 108 | $24,840 | $11,763 | 47.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 20 | 23 | $1,840 | $745.52 | 40.5% |
About Dr. Ayesha Zuberi, MD
Dr. Ayesha Zuberi, MD is a Infectious Disease healthcare provider based in Pearland, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2013. The National Provider Identifier (NPI) number assigned to this provider is 1780023044.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ayesha Zuberi, MD has received a total of $213.14 in payments from pharmaceutical and medical device companies, with $26.06 received in 2023. These payments were reported across 13 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($200.87).
As a Medicare-enrolled provider, Zuberi has provided services to 1,808 Medicare beneficiaries, totaling 4,547 services with total Medicare billing of $330,936. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Pearland, TX
- Active Since 06/20/2013
- Last Updated 06/18/2024
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1780023044
Products in Payments
- ORBACTIV (Drug) $83.28
- Fetroja (Drug) $38.33
- ZERBAXA (Drug) $28.00
- Vabomere (Drug) $25.34
- CUBICIN RF (Drug) $13.79
- MINOCIN IV (Drug) $12.40
- VABOMERE (Drug) $12.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.